Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 3/20 | 0.41 |
| ▸ | MAPT | P10636 | 4/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.40 |
| ▸ | RELA | Q04206 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA7 | P43166 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | PRKCZ | Q05513 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | JMJD7 | P0C870 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8226021 | 0.86 | NPC1 (0.35) | MAPTRAB9ANPC1NFKB1MAPK1 | |
| SCHEMBL1243723 | 0.83 | AR (0.44) | ARMAPTRAB9ANPC1NFKB1 | |
| SCHEMBL21496638 | 0.79 | CA12 (0.44) | MAPTRAB9ANPC1PDE4DCA12 | |
| SCHEMBL29882320 | 0.79 | BRD4 (0.46) | MAPTRAB9ANPC1PDE4DCA12 | |
| SCHEMBL30503125 | 0.79 | CA12 (0.44) | MAPTRAB9ANPC1PDE4DCA12 | |
| SCHEMBL1243697 | 0.79 | NUDT1 (0.44) | MAPTRAB9ANPC1NFKB1MAPK1 | |
| SCHEMBL1143703 | 0.76 | ALDH1A1 (0.48) | ARMAPTRAB9ANPC1NFKB1 | |
| SCHEMBL1244970 | 0.75 | NUDT1 (0.48) | MAPTRAB9ANPC1NFKB1MAPK1 | |
| SCHEMBL28542359 | 0.73 | MAPT (0.45) | MAPTRAB9ANPC1NFKB1MAPK1 | |
| SCHEMBL17674161 | 0.72 | L3MBTL1 (0.54) | MAPTRAB9ANPC1NFKB1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034467-A1 | DIHYDRO-PYRROLOPYRIDINE-, DIHYDRO-PYRROLOPYRIDAZINE- AND DIHYDRO-PYRROLOPYRIMIDINE-DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034467-A1 | DIHYDRO-PYRROLOPYRIDINE-, DIHYDRO-PYRROLOPYRIDAZINE- AND DIHYDRO-PYRROLOPYRIMIDINE-DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2011-02-10 | — | — | US | disclosed |
| US-20110034467-A1 | DIHYDRO-PYRROLOPYRIDINE-, DIHYDRO-PYRROLOPYRIDAZINE- AND DIHYDRO-PYRROLOPYRIMIDINE-DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2011-02-10 | — | — | US | disclosed |
| EP-2029589-A1 | DIHYDRO-PYRROLOPYRIDINE-, DIHYDRO-PYRROLOPYRIDAZINE- AND DIHYDRO-PYRROLOPYRIMIDINE-DERIVATIVES AND USE THEREOF | Bayer HealthCare AG (DE) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007137793-A1 | DIHYDRO-PYRROLOPYRIDINE-, DIHYDRO-PYRROLOPYRIDAZINE- AND DIHYDRO-PYRROLOPYRIMIDINE-DERIVATIVES AND USE THEREOF | BAYER HEALTHCARE AG (DE) | 2007-12-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034467-A1 | DIHYDRO-PYRROLOPYRIDINE-, DIHYDRO-PYRROLOPYRIDAZINE- AND DIHYDRO-PYRROLOPYRIMIDINE-DERIVATIVES AND USE THEREOF | DPYD, QDPR, DHPS | AR 4868/4885MAPT 3640/4885RAB9A 3097/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.